5/30
08:00 am
lenz
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
Low
Report
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
5/12
09:12 am
lenz
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/8
04:12 pm
lenz
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
Medium
Report
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
5/8
04:01 pm
lenz
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Medium
Report
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
5/1
04:09 pm
lenz
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024 [Yahoo! Finance]
Low
Report
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024 [Yahoo! Finance]
5/1
04:01 pm
lenz
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
Medium
Report
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
4/17
04:34 pm
lenz
LENZ Therapeutics, Inc. (NASDAQ: LENZ) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Medium
Report
LENZ Therapeutics, Inc. (NASDAQ: LENZ) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
4/15
08:18 am
lenz
LENZ Therapeutics, Inc. (NASDAQ: LENZ) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $32.00 price target on the stock.
Low
Report
LENZ Therapeutics, Inc. (NASDAQ: LENZ) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $32.00 price target on the stock.
4/15
08:11 am
lenz
LENZ Therapeutics, Inc. (NASDAQ: LENZ) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Low
Report
LENZ Therapeutics, Inc. (NASDAQ: LENZ) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
4/10
08:55 am
lenz
LENZ Therapeutics, Inc. (NASDAQ: LENZ) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $34.00 price target on the stock.
Medium
Report
LENZ Therapeutics, Inc. (NASDAQ: LENZ) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $34.00 price target on the stock.
4/3
07:09 am
lenz
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials [Yahoo! Finance]
High
Report
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials [Yahoo! Finance]
4/3
07:00 am
lenz
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
Medium
Report
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
4/2
04:10 pm
lenz
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials [Yahoo! Finance]
Low
Report
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials [Yahoo! Finance]
4/2
04:01 pm
lenz
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
Low
Report
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
3/27
08:07 am
lenz
LENZ Therapeutics, Inc. (NASDAQ: LENZ) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $28.00 price target on the stock.
High
Report
LENZ Therapeutics, Inc. (NASDAQ: LENZ) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $28.00 price target on the stock.
3/21
04:30 pm
lenz
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
Low
Report
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress